Special Issue Steatotic liver disease KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL) Clin Mol Hepatol 2025;31(Suppl):S1-S31
By improving metabolism, supporting liver function, and boosting energy, these injections help you lose weight while promoting overall health and vitality
doi: 10.3389/fendo.2023.1267383 51 LiuY.LiuQ.ZhangC.ZhaoJ.ZhangH.ChenW.et al
Combination therapy is not for everyone
The active ingredient in Ozempic, semaglutide, is not a controlled substance and typically not part of a drug screening test
The problem is friction